THE TAPE
EHC · Hospitals · $14.0B

Encompass Health Corporation Common Stock

$142.11▲ +0.79%
Last close
Relative strength
82RS
of 99, against every stock▲ +14 on the month
Powering up
Unconfirmed
+33.7%
six months against the S&P 500
52-week range
−1.2%
from the high
$92.77$143.90
Setup
flat baseplayed out
+11.5%
against the pivot at $127.50
No report date on the calendar.
Growth FLATProof PENDING
Quarter to Sep 30, revenue +9% on a year ago
11/16 O 142.76 H 143.51 L 140.61 Vol 678.5K
Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

All four are in order, fastest above slowest — every timeframe pointing the same way.

RS82
vs pivot+11.46%
Tightening0.90×
Dry-up0.88×
Up/down vol0.18
From high1%
played out6 of 9checks
Powering up
Support and resistance
Support below
$127.03
-10.6% · tested 3× · last 15 sessions ago
Resistance above
None within the last 120 sessions

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

The base has run 9.2 weeks and fell 7% from its ceiling at its deepest. The pivot is $127.50, and the stock closed 11.5% above that pivot. Its relative strength rating is 82.

Against its industry
UnconfirmedNone of the patterns above holds.
One month against the S&P 500
+14.6%
Three months against the S&P 500
+20.7%
Six months against the S&P 500
+33.7%

Its industry has too few members to make an index of, so it is read against the S&P 500 and can only be turning, caution or unconfirmed.

Peers
Same industry
Same theme
No themes — common and fine.
Catalyst roadmap
49
days
Ex-dividend in 49 days
Jan 4, 2027
  1. Ex-dividendconfirmedin 49d
    Ex-dividend date
    Jan 4, 2027
How it moves on earnings

On average 7.9% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$6.3B
+8.9% year on year
Operating margin
—
Net margin
10.2%
Free cash flow
—
Price to sales
2.21×
Price to earnings
21.8×

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Oct 28
Key takeaway
A mixed quarter: the numbers do not agree.
Revenue
$1.6B
+0.8% QoQ · +8.9% YoY
Gross margin
—
Net income
$149.9M
Positive
Free cash flow
—

What the numbers say

  • Revenue +8.9% year over year, +0.8% on the quarter
  • Good: Profitable: net income $150M
  • Good: Share count -2.5% in a year: buying back
  • Net debt $2.48B · cash $76M
Revenue by quarter
Net income
shares -2.5% in a year · net debt $2.5B

The desk’s own read

Flagged as drifting up since the report

Final read
Growth: FLAT · Economic proof: PENDING
Key question: What turns the cash flow positive?
The next test is whether the quarter repeats.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

Held by 1 of 46 tracked funds at the end of Q3 2026.

Last quarter: 1 added, 1 sold out.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
Tightening after a sharp runTape · 2026-11-10
range halved after a +17% thrust, at 141.15
No measurable effect: stocks behave like random ones over the next three sessions (887 cases over 60 nights).
New 52-week highTape · 2026-10-30
2.1x vol
Mixed: stocks have lagged random stocks by 0.9% over three sessions, not consistently enough to call (554 cases over 52 nights). Against their own sector they have lagged by 2.1%.
Closed above its 20- and 50-day on heavy volumeTape · 2026-10-30
above 20d & 50d on 2.1x volume at 131.49
Mixed: stocks have outrun random stocks by 0.2% over three sessions, not consistently enough to call (1,668 cases over 60 nights). Against their own sector they have lagged by 0.7%.
GappedTape · 2026-10-30
+7.7%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Moved 5%+ up on earningsTape · 2026-10-30
+7.7% on earnings 2026-10-28
No measurable effect: stocks behave like random ones over the next three sessions (604 cases over 42 nights).
Unusual volumeTape · 2026-10-30
3.6 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.
Reported resultsFiling · 2026-10-29
2.02
No measurable effect: stocks behave like random ones over the next three sessions (2,340 cases over 54 nights).
Earnings comingEvent · 2026-10-27
reports 2026-10-28 amc
No measurable effect: stocks behave like random ones over the next three sessions (2,970 cases over 40 nights).

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Insiders
Bought on the open market
0
Sold on the open market
6
$26,430,023 total

Sold: Price Andrew L, Darby John Patrick, COLTHARP DOUGLAS E, Tarr Mark J.

Not counted above: 23 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-10-19 Christie Edward M III · Directoraward221$27,985
2026-10-19 Reidy Christopher R · Directoraward284$36,037
2026-10-15 CARMICHAEL GREG D · Directoraward28
2026-10-15 Williams Terrance · Directoraward28
2026-10-15 SCHLICHTING NANCY M · Directoraward38
2026-10-15 HERMAN JOAN E · Directoraward81
2026-10-15 Christie Edward M III · Directoraward11
2026-10-15 Reidy Christopher R · Directoraward20

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

What lines up

6 of 9 published checks currently line up. This is a count, not a probability — nothing on this site measures how often a setup works.

Relative strength of 80 or better
Above its 50-day line
Above its 200-day line
Averages fully stacked
Within 5% of its pivot
Range tightening through the base
Volume drying up through the base
More up-volume than down-volume
Within 15% of its 52-week high
What analysts expect
Strong buy1
Buy12
Hold0
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

Checking your subscription…

X-ray
9w · 7%

The most recent of 3 completed bases.

Checking your subscription…

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
Encompass Health Corporation Common Stock (EHC) — The Tape